
LITERATURA

1. Abalovich M, Vázquez A, Alcaraz G, et al. Adequate levothyroxine doses for the treatment of hypothyroidism newly discovered during pregnancy. *Thyroid*. 2013;23(11):1479–83.
2. Adrogue HJ, Madias NE. Hyponatremia. *New Engl J Med*. 2000;342:1581–9.
3. Ali SZ, Vander Lann PA (eds). *The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes*. 3rd ed. Springer Cham; 2023;
4. Ali SZ, et al. The 2023 Bethesda System for reporting thyroid cytopathology. *J Am Soc Cytopathol*. 2023;12:319–25.
5. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. *Orphanet J Rare Dis*. 2010;5:9.
6. Arlt W, Willis DS, Wild SH, et al. United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. *J Clin Endocrinol Metab*. 2010;95(11):5110–21.
7. Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. *Endocrine Related Cancer*. 2017;24:C5–8.
8. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C et al; EUGOGO. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol*. 2021;185(4):G43-G67.
9. Bilezikian JP, Khan AA, Silverberg SJ, et al.; International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. *J Bone Miner Res*. 2022;37(11):2293–314.
10. Braunstein GD. Hypothalamic Syndromes. In: Jameson JL, DeGroot LJ, editors. *Endocrinology*. 6th ed. W. B. Saunders; 2010. p. 230–342.
11. Boccalatte LA, Higuera F, Gómez NL, et al. Usefulness of 18F-Fluorocholine Positron Emission Tomography-Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review. *JAMA Otolaryngol Head Neck Surg*. 2019;145(8):743–50.
12. Cawood TJ, Hunt PJ, O'Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? *Eur J Endocrinol*. 2009;161:513–27.

13. Cooper TG et al. World Health Organization reference values for human semen characteristics. *Human Reproduction Update*. 2010;16(3):231–45.
14. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liège, Belgium. *J Clin Endocrinol Metab*. 2006;91:4769–75.
15. Dauber A, Kellogg M, Majzoub JA. Monitoring of Therapy in Congenital Adrenal Hyperplasia. *Clin Chem*. 2010;56(8):1245–51.
16. Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. *J Clin Endocrinol Metab*. 2019;104(7):2473–89.
17. Durante C. Et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. *Eur Thyroid J*. 2023;12(5):e230067.
18. Fassnacht M, et al. ESE Clinical Practice Guidelines on the management of adrenocortical carcinoma. *Eur J Endocrinol* 2018;179(4):G1–46.
19. Fassnacht M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol*. 2023;189:G1–42.
20. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community based, cross-sectional study in Banbury (Oxfordshire). *Clin Endocrinol (Oxf)*. 2010;72:377–82.
21. Ferriman DM, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol*. 1961;21:1440–7.
22. Fisseler-Eckhoff A, Demes M. Neuroendocrine Tumors of the Lung. *Cancers*. 2012;4:777–98.
23. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2008;93:3266–81.
24. Gruber et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. *J Clin Endocrinol Metab*. 2019;104(5):1386
25. Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018, JNCCN. 2018;16:1429–40.
26. Hána V. Hypopituitarismus a diabetes insipidus centralis. Praha: Maxdorf; 2011.
27. Hána V, Kosák M, Hána V jr. Hypogonadismus u mužů a jeho léčba. *Čas Lék Čes*. 2017;156:258–65.
28. Harris PE, Bouloux PMG. *Endocrinology in clinical practice*. CRC Press; 2014.
29. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1–133.
30. Iñiguez-Ariza, Nicole M. et al. Clinical, Biochemical, and Radiological Characteristics of a Single-Center Retrospective Cohort of 705 Large

- Adrenal Tumors. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*, 2017;2(1):30–9.
31. Jameson JL, DeGroot LJ. *Endocrinology*, 6th ed. W.B. Saunders Company, 2010.
 32. Javorsky BR, Raff H, Carroll TB, et al. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays. *J Endocr Soc*. 2021;5(4):bvab022.
 33. Jiskra J. Incidentalomy štítné žlázy. *Vnitr Lek*. 2022;68(7):465–74.
 34. Kaltsas G, et al. Current Status and Controversies in adrenal incidentalomas. *Trends Endocrin Metabolism*, 2012;23(12):602–9.
 35. Kasper DL, Braunwald E, Fauci AS, et al., editors. *Harrison's Principles of Internal Medicine*. 16th ed. McGraw Hill; 2005.
 36. Katznelson L, et al. Global clinical response in Cushing's syndrome patients treated with mifepristone. *Clin Endo*. 2014;80:562–9.
 37. Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. *Endocrine Pract*. 2011;17(Suppl 4):1–44.
 38. Khan AA, Bilezikian JP, Potts JT Jr. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. On behalf of the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. *J Clin Endocrinol Metab*. 2009;94:333–4.
 39. Kršek M, Jiskra J, Krátký J. Vyšetření krku UZ. In: Marek J, Hána V, et al., editors. *Endokrinologie*. Praha; Galén: 2017.
 40. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. *Williams Textbook of Endocrinology*. 10th ed. Philadelphia: W. B. Saunders; 2003.
 41. Lebl J, Janda J, et al. *Klinická pediatrie*. Praha: Galén; 2012.
 42. Loh JA, Verbalis JG. Disorders of Water and Salt Metabolism Associated with Pituitary Disease. *Endocrinol Metab Clin N Am*. 2008;37:213–34.
 43. Marek J, et al. *Farmakoterapie vnitřních nemocí*. 4th ed. Praha: Grada; 2010.
 44. Nieman L, Raff H, DeSantis A. Diagnosis of adrenal insufficiency in adults. *Up To Date*. 2025.
 45. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab*. 2002;87(5):1941–6.
 46. Petersenn S et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. *Nature Reviews Endocrinology*. 2023;19:722–40.
 47. Refardt J, Atila C, Christ-Crain M. New insights on diagnosis and treatment of AVP deficiency. *Rev Endocr Metab Disord*. 2024;25:639–49.
 48. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. *Endocr Pathol*. 2022;33:115–54.
 49. Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. *Eur Thyroid J*. 2017;6(5):225–37.

50. Schmidbauer B, Menhart K, Hellwig D, et al. Differentiated Thyroid Cancer-Treatment: State of the Art. *Int J Mol Sci*. 2017;18(6).pii:E1292.
51. Smith DM, McKenna K, Thompson CJ. Hyponatremia. *Clin Endocrinol (Oxf)*. 2000;52:668–78.
52. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Europ J Endocrinol*. 2014;170:G1–47.
53. Speiser PW, Azziz R, Baskin LS, et al.; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2010;95(9):4133–60. Erratum in: *J Clin Endocrinol Metab*. 2010;95(11):5137. Erratum in: *J Clin Endocrinol Metab*. 2021;106(7):e2853.
54. Tajar A, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). *J Clin Endocrinol Metab*. 2012;97(5):1508–16.
55. Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. *Eur J Endocrinol*. 2011;164:851–70.
56. Thoracic Tumours. In: WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Publications, 2021. Vol 5.
57. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *Aging Male*. 2009;12(1):5–12.
58. Whitaker MJ, Debono M, Huatan H, et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. *Clin Endocrinol (Oxf)*. 2014;80(4):554–61.
59. Widimský J. Mineralokortikoidně podmíněné hypertenze. In: Marek J, Hána V, et al., editors. *Endokrinologie*. Praha: Galén; 2017; p. 349–54.
60. Wilson JD, Foster DW. *Williams Textbook of Endocrinology*. 10th ed. W.B. Saunders; 2003.
61. Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol*. 2007;66:607–18.